Aura Biosciences (NASDAQ:AURA) Upgraded to “Strong-Buy” at Lifesci Capital

Aura Biosciences (NASDAQ:AURA) was upgraded by equities researchers at Lifesci Capital to a “strong-buy” rating in a report issued on Friday,Zacks.com reports.

A number of other research firms have also recently commented on AURA. Cowen restated a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. Scotiabank boosted their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a report on Friday, October 18th. Finally, BTIG Research lifted their price objective on Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Price Performance

Shares of AURA stock opened at $7.85 on Friday. The company has a market cap of $392.12 million, a price-to-earnings ratio of -4.54 and a beta of 0.30. The stock’s fifty day moving average price is $8.28 and its 200 day moving average price is $8.90. Aura Biosciences has a 1-year low of $6.63 and a 1-year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02. As a group, equities research analysts anticipate that Aura Biosciences will post -1.66 earnings per share for the current year.

Insider Transactions at Aura Biosciences

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the transaction, the insider now directly owns 151,693 shares in the company, valued at approximately $1,419,846.48. This trade represents a 7.23 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 28,778 shares of company stock valued at $240,706. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

Large investors have recently bought and sold shares of the company. American Century Companies Inc. acquired a new stake in shares of Aura Biosciences in the 2nd quarter valued at approximately $119,000. Dimensional Fund Advisors LP raised its holdings in shares of Aura Biosciences by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after acquiring an additional 41,711 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Aura Biosciences by 26.3% during the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after buying an additional 15,000 shares during the period. The Manufacturers Life Insurance Company increased its stake in Aura Biosciences by 14.6% in the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after purchasing an additional 8,194 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Aura Biosciences during the third quarter worth approximately $169,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.